Đang chuẩn bị liên kết để tải về tài liệu:
Bóa cáo y học: "Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care cung cấp cho các bạn kiến thức về ngành y đề tài: Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. | Available online http ccforum.eom content 10 3 R74 Open Access Research Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa activated treatment in severe sepsis Jean-Louis Vincent1 James O Brien Jr2 Arthur Wheeler3 Xavier Wittebole4 Rekha Garg5 Benjamin L Trzaskoma5 and David P Sundin5 Department of Intensive Care Erasme Hospital Free University of Brussels Brussels Belgium 2Division of Pulmonary Critical Care and Sleep Medicine The Ohio State University Medical Center 201 Davis HLRI 473 West 1 2th Avenue Columbus OH 43210 USA 3Department of Medicine Vanderbilt University Medical Center North T-1 218 Nashville TN 37232-2650 USA 4Department of Intensive Care St Luc University Hospital UCL Avenue Hippocrate 10 1 200 Brussels Belgium 5Lilly Research Laboratories LCC MC 510 07DC4077 Eli Lilly and Company Indianapolis IN 46285 USA Corresponding author Jean-Louis Vincent jlvincen@ulb.ac.be Received 30 Jan 2006 Revisions requested 6 Mar 2006 Revisions received 16 Mar 2006 Accepted 5 Apr 2006 Published 9 May 2006 Critical Care 2006 10 R74 doi 10.1186 cc4909 This article is online at http ccforum.com content 10 3 R74 2006 Vincent et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction Several studies have indicated that early identification and treatment of patients with severe sepsis using standard supportive care improves outcomes. Earlier treatment with drotrecogin alfa activated DrotAA may also improve outcomes in severe sepsis. Using a recently constructed integrated severe sepsis database our objectives in this study were to describe the influence of baseline clinical characteristics on timing of DrotAA treatment in patients with severe sepsis to evaluate the .